Impact of KEAP1/NFE2L2/CUL3 mutations on duration of response to EGFR tyrosine kinase inhibitors in EGFR mutated Non-Small Cell Lung Cancer

Epidermal Growth Factor Receptor (EGFR) mutations occur in approximately 30% of cases of non-small cell lung cancer (NSCLC) and are important drivers in the development of lung adenocarcinoma. [1] The last few years have seen the development of several FDA approved EGFR targeted therapies, which have significantly improved progression free survival while achieving more favorable side effect profiles compared to chemotherapy for patients with sensitizing mutations in EGFR [2 –34]. However, despite the development of new therapies, acquired resistance to EGFR tyrosine kinase inhibitors (TKIs) is inevitable and progression usually occurs within 10-20 months of starting treatment.
Source: Lung Cancer - Category: Cancer & Oncology Authors: Source Type: research